【24h】

The long war

机译:漫长的战争

获取原文
获取原文并翻译 | 示例
           

摘要

On october 8th researchers announced progress in developing a vaccine against malaria. GlaxoSmithKline (gsk), a British pharmaceutical firm, said it would seek regulatory approval next year for this vaccine, called rts.s. gsk and its charitable partner, the path Malaria Vaccine Initiative, also revealed new data showing the vaccine's effect in children. This is good news, but rts,s will not vanquish malaria by itself. There were, according to the World Health Organisation (who), about 200m cases of malaria around the world in 2010, with 660,000 deaths, 90% of which were in Africa, mostly of young children. The prospect of a vaccine is therefore exciting to patients and health experts alike. But developing one is difficult. Malarial parasites, though small and single-celled, are much more complex than the bacteria and viruses that are the usual targets of vaccines. To date there has been no successful vaccine against such a complex organism. Work on rts,s has been going on for decades.
机译:10月8日,研究人员宣布了研发抗疟疾疫苗的进展。英国制药公司葛兰素史克(GSK)表示,明年将寻求监管部门批准这种名为rts.s的疫苗。 gsk及其慈善合作伙伴“疟疾疫苗倡议”(Malaria Vaccine Initiative)路径也透露了新数据,显示出该疫苗对儿童的影响。这是个好消息,但是rts,s本身不会消除疟疾。根据世界卫生组织(世卫组织)的数据,2010年全世界约有2亿例疟疾病例,造成660,000例死亡,其中90%在非洲,主要是幼儿。因此,疫苗的前景令患者和健康专家们兴奋不已。但是开发一个是困难的。疟原虫虽然很小并且是单细胞的,但是比作为疫苗常用靶标的细菌和病毒要复杂得多。迄今为止,还没有针对这种复杂生物的成功疫苗。 rts,s的工作已经进行了数十年。

著录项

  • 来源
    《The economist》 |2013年第8857期|86-86|共1页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号